Adam is the global head of Biogen’s biosimilars business unit value and access team. Adam has more than 15 years of experience in value and access. Prior to Biogen, he was at Novo Nordisk in global, regional and affiliate roles including head of the company’s global market access and market access Europe. After Novo Nordisk, Adam was responsible for Ilaris (canakinumab) market access at Novartis. Before Biogen, he was the head of global market access for CardioMetabolic at Takeda Pharmaceuticals.